Petros Pharmaceuticals, Inc. Accrued Liabilities, Current
Petros Pharmaceuticals, Inc. (PTPI) had Accrued Liabilities, Current of $216.54 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Liabilities, Current $216.54K.
- 2026-03-31: Accrued Liabilities, Current $190.63K.
- 2025-12-31: Accrued Liabilities, Current $142.49K.
- 2025-09-30: Accrued Liabilities, Current $512.03K.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $216.54K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $190.63K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $142.49K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $512.03K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $260.62K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $199.70K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $99.64K 10-K · filed 2026-04-15 | $6.46M 10-K · filed 2025-03-31 |
| 2024-09-30 | $6.54M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $6.67M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $6.33M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $5.36M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $3.87M 10-Q · filed 2023-11-15 | |
| 2023-06-30 | $4.78M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $3.61M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $3.63M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $4.48M 10-Q/A · filed 2022-11-15 | |
| 2022-06-30 | $4.01M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $5.51M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $11.96M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $11.59M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $13.76M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $15.38M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $14.68M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |